Ulrich Granzer
Ulrich Granzer, PhD is owner of Granzer Regulatory Consulting and Services (www.granzer.biz), a company with 20 employees. He and his firm are working as consultants for strategic drug development and regulatory affairs. The company has clients in big pharma as well as new and established biotech companies. The focus of the company lies on all aspects of drug development and regulatory affairs. Ulrich Granzer, who is a pharmacist by training, has major experience in drug development and regulatory affairs of biotech products and small molecules, which he gained in addition to his current role, in leading positions at Glaxo, BASF Pharma – Knoll (Vice president regulatory centers), and Bayer (VP global regulatory affairs).
He was and is involved in the development and registration of products targeting cardiovascular and endocrinological diseases (diabetes, heart failure), HIV, asthma, pain, chemotherapy induced emesis, several biological compounds directed against the sequelae of stroke, septic shock, cancer, and autoimmune diseases like rheumatoid arthritis. He had major involvement with the program for the first fully human anti TNF antibody, now marketed as Humira. Additionally, one major aspect is all work summarized under the headline “paediatrics”.
He has a track record of working on more than 200 NME’s and MNE - submissions in several major indications like Diabetes, Heart Failure, HIV, rheumatoid arthritis, asthma, pain, cancer, stroke, tissue regeneration, neurological and neurodegenerative disorders with small molecules and biologicals as well, including Orphan Drug Designations and approvals in the EU, the US and other major markets.
or